Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MabCure starts trial of ovarian cancer diagnostic

This article was originally published in Clinica

Executive Summary

MabCure has started a trial to evaluate its monoclonal antibodies (MAbs) in diagnosing ovarian cancer. The study, which is being carried out at the Ramathibodi Hospital, Mahidol University in Bangkok, Thailand, will enrol patients suspected of having the disease. A spokesperson for MabCure (New York and Hasselt, Belgium) declined to give further details, but did say that the company hopes the test will eventually be used for diagnosing ovarian cancer earlier than is currently possible. The disease is often detected at a late stage, leading to a low survival rate, but five-year survival rates could be increased to over 90% if it was identified earlier. MabCure’s is also developing MAbs for other cancers, including prostate and colorectal.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT045175

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel